Shanghai biotech Stemirna Therapeutics has begun a Phase 1 trial for its COVID-19 mRNA vaccine. The company has been working on the drug since spring 2021 (China.Table reported). Three other Chinese mRNA vaccines are already undergoing clinical trials. The hope now rests on the four vaccine candidates to break the country out of the lockdown trap. A phase 1 trial will initially test a new agent on a small number of people to determine its effects.
Continue reading now
Get 30 days of free access to the Decision Brief to read these and more quality news every day.
Are you already a guest at the China.Table? Log in now